Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Kisspeptin-10 | Pentadeca Arginate (PDA) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation. | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. |
| Timing | Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity. | Administer on an empty stomach. Inject near site of injury for localized effect. |
| Cycle Duration | Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis. | 4-12 weeks depending on therapeutic target. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.
Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.
Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.
Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →